Browse News

Found 40 articles

• Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γD2 T cell therapy against EGFR-expressing solid tumors

  3/28/2023

  Acepodia announced the upcoming poster presentation of new preclinical data for ACE2016, a gamma delta-2 T cell therapy designed to target EGFR expressing solid tumors.

• Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

  11/3/2022

  Acepodia announced the upcoming poster presentation of new preclinical data for ACE1831, a gamma delta 2 T cell therapy being developed as a treatment for non-Hodgkin's lymphoma.

• Stem Cells Market Size to Hit Around USD 31.88 BN by 2030

  10/26/2022

  The global stem cells market size was surpassed at USD 11.9 billion in 2021 and is expected to hit around USD 31.88 billion by 2030, growing at a CAGR of 11.57% from 2022 to 2030.

• Acepodia Congratulates Laureates of the 2022 Nobel Prize in Chemistry and Shares the Excitement to Translate Click Chemistry into a New Class of Investigational Therapies

  10/7/2022

  Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation platform technology to address gaps in cancer care, joins the academic community in congratulating laureates of the 2022 Nobel Prize in Chemistry.

• Natural Killer (NK) Cell Therapeutics Market to See Remarkable CAGR Growth of 40.9% with Share, Size, Key Players, and Trends forecast

  7/6/2022

  Natural Killer (NK) Cell Therapeutics marketing report provides complete background analysis of the industry which includes an assessment of the parental market.

• Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

  6/20/2022

  Acepodia today announced that it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase 1, first-in-human, multi-center clinical study of its ACE1831 in patients with non-Hodgkin's lymphoma.

• Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer

  6/6/2022

  Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer cell therapies that are safe and accessible to cancer patients, announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer.

• Gamma Delta T Cell Therapy Represents One of the Most Promising T Cell Therapies in Clinical Development

  4/21/2022

  The "Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering.

• Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

  3/21/2022

  Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update.

• IO Biotech Announces Appointment of David V. Smith to its Board of Directors

  3/3/2022

  IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors.

• Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board

  1/6/2022

  Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation platform technology to address gaps in cancer care, announced it has appointed David V. Smith to its Board of Directors and Elizabeth Smith and Richard Lopez, M.D., to its Scientific Advisory Board.

• Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies

  12/2/2021

  Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation platform technology to address gaps in cancer care, announced the closing of a $109 million Series C financing round led by Digital Mobile Venture and other new and existing investors.

• Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of DirectorsFormer Chief Medical Officer of Juno Therapeutics Brings Decades of Oncology Clinical Development Expertise

  12/1/2021

  Indaptus Therapeutics, Inc., announces the appointment of Mark Gilbert, M.D., to its Board of Directors.

• Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments

  11/3/2021

  Acepodia today announced the appointments of Robin Andrulevich to the company’s Board of Directors and Eileen Higham, Ph.D., to the company’s Scientific Advisory Board.

• Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors

  9/16/2021

  Acepodia reported new interim data from an ongoing Phase 1 dose escalation study demonstrating feasibility with ACE1702, the company’s most advanced investigational antibody effector cell therapy, in development for patients with advanced HER2-positive tumors.

• Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress

  9/13/2021

  Acepodia today announced that it will present new interim data from an ongoing Phase 1 study ( NCT04319757 ) evaluating ACE1702 at the European Society of Medical Oncology (ESMO) 2021 Annual Congress being held virtually September 16-21, 2021.

• Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers

  6/7/2021

  Acepodia, today announced that an article describing the efficacy profile of ACE1702, Acepodia’s novel, off-the-shelf natural killer (NK) cell therapy against HER2-expressing solid tumors, was published in the journal Cancers.

• Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers

  5/19/2021

  Preclinical data demonstrate potential of off-the-shelf, NK-like gamma-delta T cells in developing cell therapies for the treatment of cancers ACE1831, an allogeneic cell therapy candidate targeting hematological cancers, demonstrates prolonged survival in vivo

• Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy OfficerKey executive hires strengthen Acepodia’s expanding leadership team and position the company for upcoming growth catalysts

  5/11/2021

  Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, announced the appointments of Thorsten Graef, M.D., Ph.D., as chief medical officer and Michael Brock as chief strategy officer.

• Acepodia CEO and Co-founder, Sonny Hsiao, Ph.D., to Present at Allogeneic Cell Therapies Summit 2021

  5/10/2021

  Acepodia , a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny Hsiao, Ph.D., chief executive officer and co-founder of Acepodia, has been invited to speak at the Allogeneic Cell Therapies Summit 2021 taking place virtually May 17-19, 2021.